China Biopharma Landscape, Q2 2026: The US Translation Gap

China’s biopharma constraint is translation, not innovation

China now originates roughly half of the world’s bispecific antibodies, antibody-drug conjugates (ADCs) and CAR-T therapies, yet only 34 of about 1,025 China-originated drugs approved somewhere in the world are approved in the US. Sleuth’s April 2026 data counts about 335 licensing deals that US and European buyers have signed for China-originated assets since April 2021. In Sleuth’s reading, China’s constraint is translation, not innovation: meeting the evidence, manufacturing and supply-chain standards that FDA approval requires.

That translation gap decides who captures the value of China’s pipeline. It explains why Western pharma licenses Chinese assets rather than waiting to compete with them, why deals are being signed earlier, and why regulatory readiness, not target novelty, is the advantage US biotechs still hold. The figures below come from Sleuth’s April 2026 snapshot of about 18,350 active China-originated assets, matching the downloadable report; Sleuth’s live China coverage now spans about 22,000 programs.

Only about 2,300 of China’s innovative assets are in late-stage development

Oncology leads, and seven other therapeutic areas each exceed 1,000 programs

The snapshot covers mainland China, Hong Kong, Macao and Taiwan. Of its roughly 18,350 assets, about 17,500 are innovative drugs and the other 850 or so are generics and biosimilars. Oncology accounts for roughly 9,950 assets, and seven other therapeutic areas each exceed 1,000, so Western teams in autoimmune, metabolic and hematologic disease also compete with China-originated assets. Growth accelerated after China began reforming drug review in 2015; the National Medical Products Administration (NMPA) accepted about 2,300 investigational new drug (IND) applications for innovative drugs in 2023 alone.

Immunology and inflammation leads China’s late-stage pipeline

Of the roughly 17,500 innovative assets, about 11,200 are preclinical, about 4,000 are in early clinical development (IND through Phase I/II) and about 2,300 are in Phase II or later, 13% of the full pipeline. Immunology and inflammation (I&I) leads the late-stage group with about 830 assets, ahead of oncology (about 785) and infectious disease (about 665), and only about 510 assets are currently in Phase III.

The late-stage mix is the supply of licensable assets for the next few years, and it is broader than China’s oncology-heavy reputation suggests, so BD teams that scout China mainly for cancer assets will miss much of it. And with so few assets in Phase III, near-term pressure on Western companies will come through mid-stage data and licensing deals, not Chinese launches in Western markets.

China holds more than 40% of the global pipeline in 11 modalities

Bispecifics, ADCs, CAR-T and PROTACs are the main battlegrounds

China’s share of the global innovative pipeline exceeds 40% in 11 of the 28 modalities Sleuth tracked. Bispecific antibodies, ADCs, CAR-T therapies and proteolysis-targeting chimeras (PROTACs) each have global pools of about 1,000 assets or more, and China originates about half of each. Some smaller platforms pass 60% China share, but their global pools of roughly 80 to 500 assets offer Western buyers few licensing targets.

China’s lead here rests less on discovery than on translational throughput: fast enrollment, low-cost manufacturing and deep contract development capacity. Western developers in these modalities are competing with China on speed and cost.

Gene therapy, antisense and CNS targets remain white space

China’s share falls to about 20% in gene therapy and about 17% in antisense oligonucleotides. The same pattern appears in rare disease (about 15%) and neurology and psychiatry (about 19%). Five of seven example white-space targets are central nervous system (CNS) receptors, where long trials and subjective endpoints cancel out China’s fast patient enrollment. The common thread is development complexity that China’s manufacturing and enrollment advantages cannot shortcut. Western companies face the least China-originated competition here, and buyers have the fewest Chinese assets to license.

China-to-West licensing grew about 5.6x between 2021 and 2025

Deal count, upfront payments and the buyer pool rose together

Chinese companies signed about 335 out-licensing deals with US and European buyers between April 2021 and April 2026. Annual deals grew from 19 in 2021 to 107 in 2025, about 5.6x, and disclosed upfront payments grew about 7x, from about $0.8 billion to $5.4 billion. The number of Western buyers active each year rose from 17 specialty firms to 84 companies, including all of the top 20 Western pharma companies. Only about 51% of deals disclose upfronts, so the visible capital understates the real flow.

Upfronts growing faster than volume, along with 2025 mega-deals that reset pricing ceilings, point to rising seller power. The wider buyer pool shows Chinese assets have become a standard pipeline source for large Western pharma, not a niche bet by specialty firms.

January through April 2026 brought 36 deals, a pace of about 108 for the year, level with 2025. Five novel China-originated assets have reached FDA approval since 2022.

AstraZeneca leads Western buyers with 17 deals worth about $42 billion

AstraZeneca has signed 17 deals for China-originated assets, with about $42 billion in disclosed value including milestones. GSK, Merck, Novartis and Eli Lilly have each signed eight or nine deals worth $14 billion to $20 billion. Executives at these companies describe China as a source of assets for their global pipelines rather than mainly as a commercial market. AstraZeneca has paired its repeat buying with R&D infrastructure in China and has committed $15 billion to the country through 2030.

Western buyers are licensing Chinese assets earlier

Preclinical deals grew about 8x between 2021 and 2025, to 39 a year, while Phase III and later deals doubled from 10 to 20. Later-stage signings stalled in 2024 amid uncertainty over the BIOSECURE Act, which Congress was then debating, and preclinical deals rose to 59% of that year’s total. The preclinical share fell back to 41% in 2025 as delayed later-stage deals closed. ADCs account for 53% of preclinical deals and antibodies for 25%, so buyers source early in complex modalities and later in validated ones.

Earlier entry means buyers take on more of the translation work themselves, from generating evidence the FDA will accept to bringing manufacturing up to Western standards. That is where a Western partner adds value, and where diligence on a Chinese asset has to start.

About 177 Chinese sellers compete for Western licensing deals

The 10 most active sellers account for about a quarter of deals

About 177 Chinese companies have out-licensed assets to US and European buyers, and the 10 most active account for about 80 deals, 25% of the total. Biocytogen leads with 21 deals, followed by Hengrui Pharmaceuticals with 11 and Harbour BioMed with 9. Hansoh, Kelun-Biotech, Bio-Thera, Formosa Pharmaceuticals and DualityBio have six each. Only about 21% of deals involve a seller and buyer that have worked together before, so prior relationships do not guarantee future access. For BD teams, that argues for scanning the whole seller ecosystem rather than relying on a few repeat partners.

GLP-1R, DLL3, TSLP and TL1A draw more deals than their pipeline size predicts

Pipeline depth does not predict Western deal interest for every target. GLP-1 receptor (GLP-1R) programs drew about 11 deals from a China pipeline of only about 180 assets, the strongest deal-to-pipeline ratio among targets with more than 100 China-originated assets (see how China and the West are building different obesity drugs). DLL3, TSLP and TL1A each have fewer than about 50 China-originated assets but drew four to five deals apiece. FAP has about 165 China-originated assets but no Western deals, likely because Western companies already have a sizable FAP pipeline of their own (about 139 assets outside China). PD-1 and PD-L1 have the deepest China pipeline, about 570 assets, but most are novel combinations rather than monotherapies, which helps explain why deal interest lags. Deal interest follows gaps in Western pipelines more than depth in China’s: buyers license where they lack strong programs of their own.

China-originated assets lose US presence as they advance toward approval

About 1,025 China-originated assets are approved somewhere in the world, but only 34 are approved in the US, about 3%, or roughly one in 30. Sleuth compared each asset’s furthest stage worldwide with its furthest stage in the US. At Phase I, the US count is about 19% of the global count (about 800 against 4,250), and at Phase III it is about 15% (about 75 against 510). The steepest drop comes between Phase III and approval, when chemistry, manufacturing and controls (CMC) readiness and acceptance of the clinical evidence become hard gates. CMC readiness also limits which Chinese assets Western partners can realistically license.

This erosion is the opening for Western companies. The capabilities that stop Chinese assets, including regulatory strategy, CMC and evidence generation for the FDA and European regulators, are ones Western partners already have, which is why licensing remains the main route into the US. The open question is whether the roughly 19% US footprint at Phase I holds up in later stages or erodes the same way.

About 39% of the barriers to US translation that Sleuth identified are tied to BIOSECURE-style policy risk, which shows up as a vendor and supply-chain problem. In practice that means longer diligence, costly vendor switches and CMC rework, and sponsors holding off on US and European filings until their contractor stack is clean.

The BIOSECURE Act became law in December 2025 in the fiscal 2026 National Defense Authorization Act. It bars US federal agencies from buying biotechnology equipment or services from designated “biotechnology companies of concern,” or contracting with companies that use them, so it targets manufacturing and contract services, not licensing deals. In June 2026 the Pentagon added WuXi AppTec to its Section 1260H list, which feeds the first list of companies of concern due from the Office of Management and Budget by December 2026. Existing contracts are grandfathered for five years.

ADCs, bispecifics and cell therapy follow different competitive patterns in China

China’s roughly 865 ADCs spread across about 150 targets

China originates about 865 ADCs, about 47% of the roughly 1,840 in development worldwide (see the global ADC payload landscape). No target accounts for more than about 10%, and the nine largest targets together account for only about 28%. HER2 is the most crowded, with about 64 assets, including about 11 in Phase III or later. Claudin 18.2 (CLDN18.2) has about 5 late-stage assets out of about 18, the highest late-stage share among the nine largest targets. By indication, only 3 of 77 non-small cell lung cancer (NSCLC) ADC programs have reached Phase III or later, so NSCLC’s crowding is mostly early-stage. Gastric cancer leads late-stage counts with 9 programs, and gastroesophageal junction cancer has the highest late-stage share at 24%, which makes them the first places late-stage ADC competition will arrive.

Topoisomerase I inhibitors have overtaken MMAE as the leading ADC payload

About 425 of China’s ADCs disclose payload data. Among them, topoisomerase I inhibitors lead with 193 (about 46%), ahead of monomethyl auristatin E (MMAE) with 121 (about 28%). Enhertu and Trodelvy validated the class commercially, and China’s camptothecin supply chain made the switch easy. Another 71 ADCs carry other or novel payloads.

China’s roughly 900 bispecifics cluster into three mechanisms

China originates about 900 bispecific antibodies, about 48% of roughly 1,900 worldwide. They group into targeted receptor combinations, checkpoint combinations and CD3 T-cell engagers. Among the 14 most common target pairs, EGFR plus c-Met accounts for 33 of 55 targeted-combination programs, while the checkpoint and T-cell engager clusters spread across five or six target pairs each. Unlike ADCs, bispecifics have real depth outside oncology, but that work is early. Depending on the indication, about 47% (lupus) to 94% (autoimmune disease) of non-oncology programs are still preclinical. Even so, licensing deals are already flowing into autoimmune bispecifics, and four China-originated NSCLC bispecifics had reached Phase III or later by April 2026, putting them into registrational competition with Western assets within 12 to 18 months of that date. Western companies now need to track China in both oncology and immunology.

Hospital-based CAR-T gives China an early lead in autoimmune cell therapy

Sleuth’s cell and gene therapy landscape covers clinical-stage programs only. It counts about 1,275 China-originated programs, about 44% of the roughly 2,875 in the landscape worldwide. Hospital-based CAR-T manufacturing, built for blood cancers, now supports autoimmune programs, including 71 in lupus, 47 in systemic sclerosis and 27 in ANCA-associated vasculitis. About 42 programs have reached Phase III or beyond, including two approved CD19 CAR-Ts and CARsgen’s CLDN18.2 CAR-T, which was at filing in April 2026 and was approved in China in June 2026 for previously treated CLDN18.2-positive gastric cancer. Rapid enrollment in investigator-initiated trials means China-originated programs will produce the first clinical data in many niche autoimmune settings before Western competitors enter.

Academic hospitals and research institutes originate about 37% of these programs, a development model with no parallel in ADCs or bispecifics. Of about 478 originating institutions, 419 work only in cell and gene therapy, so ADC or bispecific partnerships rarely open doors here, and Western BD teams often face hospitals as counterparties, with different IP and deal-structure diligence. China’s share is about 20% in gene therapy, against 45% to 50% in cell therapy.

EGFR, HER2 and BCMA each exceed 100 programs across all three modalities

Forty-one targets appear in all three of China’s ADC, bispecific and cell and gene therapy pipelines. EGFR, HER2 and BCMA each exceed 100 programs across the three, a layered position that single-modality entrants cannot match. CD20 has about 44 China-originated programs across these modalities (2 ADCs, 18 bispecifics and 24 cell and gene therapies) but no licensing deals with Western buyers. Targets that appear in all three modalities are the leading indicator of where China-originated assets will set the competitive standard, and CD20 is the one Western deal teams have so far passed over.

What China’s pipeline means for Western pharma and biotech

Sleuth’s report closes with three priorities for each audience, based on its interpretation of the data above.

Western pharma: fit portfolios to China’s deal flow and plan for policy risk

Position portfolios to work with China’s out-licensing flow. AstraZeneca, Merck, Novartis and GSK have already placed bets across oncology, metabolic disease and I&I, so the useful question is where opportunities remain, such as oncology targets with repeated China licensing activity but no top-20 pharma buyer yet.

Build for BIOSECURE optionality. About 39% of the barriers to US translation are sensitive to policy risk, so deal terms need fallback provisions and manufacturing that can move to another vendor.

Expect autoimmune cell therapy data from China first. China’s 71 lupus, 47 systemic sclerosis and 27 ANCA-associated vasculitis cell and gene therapy programs will generate first-mover datasets before most Western programs reach the clinic, and that data will be licensable.

US biotech: compete on translation readiness, not target novelty

Lean into translation advantage. A US biotech with a clean CMC package and Phase II data in a crowded target such as HER2, TROP2 or PD-L1 combinations holds a differentiated position. Regulatory readiness, not the target itself, is the advantage.

Treat the translation gap as a moat. More than 95% of China-originated approved assets have no US approval. Western regulatory, CMC and evidence-generation capabilities remain the bottleneck, and they are what a US biotech brings to a China partnership or a competitive race.

Diligence the long tail instead of avoiding crowded modalities. China’s ADCs spread across about 150 targets and its bispecifics across about 375 target pairs, so the landscape is diversified rather than concentrated. Scanning it systematically is how to find differentiated assets, or differentiated competitors, before a rival does.

What Sleuth expects in China biopharma through 2029

These predictions are Sleuth’s analytical interpretation, looking beyond what the data shows today.

• Most Chinese companies will stay in early-stage discovery and out-license their assets. China’s domestic market does not pay premium prices for innovative drugs, so out-licensing pays better than end-to-end development.
• Autoimmune CAR-T, starting with lupus and systemic sclerosis, will be the first area where China-originated clinical data set the global standard of care.
• The roughly 177 sellers will consolidate around about 30 “export-grade” platforms that meet FDA CMC standards, keep BIOSECURE-compliant supply chains and run multi-ethnic Phase I studies.
• A washout is coming in early-stage ADCs and bispecifics, so BD teams should keep valuations disciplined over the 12 to 18 months after April 2026. Programs that survive will command a premium once the field thins.
• China’s pipeline volume will not translate into matching value capture. China and AI are cutting the cost of making molecules, so the bottleneck moves to novel target discovery upstream and differentiated global registrational trials downstream, leaving China strongest in fast, low-cost Phase I proof of concept.

How Sleuth built this analysis

Pipeline scope and stages

Sleuth Intelligence’s pipeline data covers active assets originated in mainland China, Hong Kong, Macao and Taiwan: about 18,350 in the April 2026 snapshot, including about 17,500 innovative drugs and about 850 generics and biosimilars. Late stage means Phase II through approved, and Phase I includes IND and Phase I/II. Therapeutic areas overlap, so their counts can sum to more than the total. Sleuth’s live China coverage now spans about 22,000 programs.

China share and white space

China share is China’s innovative asset count divided by the global innovative asset count for each of 28 modalities. Modalities above 40% count as China-dominant, and white space means a China share below about 20%.

Deal data

The deal set covers about 335 out-licensing deals from Chinese companies to US and European buyers, April 2021 through April 2026. Deal values include upfront and milestone payments where disclosed, and about 51% of deals disclose upfronts. Buyers are counted per calendar year, and 2026 figures cover January through April.

US translation

For each stage, Sleuth compared the number of assets whose furthest stage worldwide is that stage with the number whose furthest US stage is that stage. An asset in Phase III elsewhere with no US activity counts as preclinical in the US view.

Modality landscapes

The modality landscapes cover about 865 China-originated ADCs (of about 1,840 worldwide), 900 bispecifics (of about 1,900) and 1,275 cell and gene therapy programs (of about 2,875). The cell and gene therapy landscape covers clinical-stage programs only, and the academic classification of originators is approximate.

Interpretation

Mechanism clusters, white-space explanations, the implications for Western pharma and biotech, and the 2029 predictions are Sleuth’s analytical interpretation rather than direct findings from the data.

Counts are rounded. Pipeline, company and deal figures are as of April 2026 unless otherwise noted, and BIOSECURE Act developments and later approvals are current as of September 2026.

Frequently asked questions about China’s biopharma landscape

How large is China’s biopharma pipeline?

Sleuth’s April 2026 snapshot counted about 18,350 active China-originated assets, about 17,500 of them innovative drugs. Oncology leads with roughly 9,950, and seven other therapeutic areas each exceed 1,000. Sleuth’s live China coverage now spans about 22,000 programs.

Which therapeutic area leads China’s late-stage pipeline?

Immunology and inflammation leads, with about 830 of the roughly 2,300 innovative China-originated assets in Phase II or later as of April 2026, ahead of oncology at about 785. About 510 assets are currently in Phase III.

How much of global ADC and bispecific development comes from China?

About half. China originates about 865 of roughly 1,840 ADCs worldwide (about 47%) and about 900 of roughly 1,900 bispecific antibodies (about 48%), based on Sleuth’s April 2026 data.

Which Western pharma companies license the most Chinese drug assets?

AstraZeneca leads with 17 deals for China-originated assets, worth about $42 billion in disclosed value including milestones. GSK, Merck, Novartis and Eli Lilly have each signed eight or nine deals worth $14 billion to $20 billion. These deals are part of about 335 Chinese out-licensing deals with US and European buyers from April 2021 to April 2026.

How many China-originated drugs reach the US market?

Few. About 1,025 China-originated assets are approved somewhere in the world, but only 34 are approved in the US, roughly one in 30. At Phase I, the US count is about 19% of the global count. The steepest drop comes between Phase III and approval, when CMC readiness and acceptance of the clinical evidence become hard gates. Five novel China-originated assets have reached FDA approval since 2022.

What does China’s pipeline mean for Western pharma and biotech companies?

In Sleuth’s view, China’s constraint is translation rather than innovation, and that shapes the response. Western pharma should fit portfolios to China’s out-licensing flow, build BIOSECURE fallback provisions into deals and prepare for autoimmune CAR-T data from China. US biotechs should compete on regulatory and CMC readiness rather than target novelty, and diligence China’s fragmented ADC and bispecific pipelines systematically.

Does the BIOSECURE Act restrict licensing deals with Chinese biotech companies?

Not directly. The BIOSECURE Act, enacted in December 2025, restricts US federal contracting involving biotechnology equipment and services from designated companies of concern, which mainly affects manufacturing and contract research services. In Sleuth’s data, BIOSECURE-style vendor and supply-chain risk accounts for about 39% of the barriers that keep China-originated assets from reaching the US, and later-stage licensing stalled in 2024 while the bill was debated.

What role do academic hospitals play in China’s cell and gene therapy pipeline?

Academic hospitals and research institutes originate about 37% of China’s clinical-stage cell and gene therapy programs. Their CAR-T manufacturing, built for blood cancers, now supports autoimmune programs, including 71 in lupus, 47 in systemic sclerosis and 27 in ANCA-associated vasculitis.

How current is this analysis?

Pipeline, company and modality figures come from Sleuth’s April 2026 snapshot, and deal figures cover April 2021 through April 2026. The BIOSECURE Act context is current as of September 2026. Sleuth’s live China coverage has since reached about 22,000 programs.